incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
There he again showed the image of parabolic patches of light on the photographic plate (see image), which suggested two species of neon nuclei with different mass-to-charge ratios. He wrote "There can, therefore, I think, be little doubt that what has been called neon is not a simple gas but a mixture of two gases, one of which has an atomic weight about 20 and the other about 22. The parabola due to the heavier gas is always much fainter than that due to the lighter, so that probably the heavier gas forms only a small percentage of the mixture." F. W. Aston subsequently discovered multiple stable isotopes for numerous elements using a mass spectrograph, related to Thomson's method. In 1919 Aston studied neon with sufficient resolution to show that the two isotopic masses are very close to the integers 20 and 22, and that neither is equal to the known molar mass (20.2) of neon gas. This is an example of Aston's whole number rule for isotopic masses, now known to be exceptionless, which states that large deviations of elemental molar masses from integers are due to the fact that the element is a mixture of isotopes. Aston similarly showed in 1920 that the molar mass of chlorine (35.45) is a weighted average of the almost integral masses for the two isotopes 35Cl and 37Cl.
== Pharmacokinetics == Lamivudine is well absorbed in the body and distributes widely into the extravascular space. Oral bioavailability is >80% and overall metabolism is insignificant where approximately 95% of the drug is found unchanged in the urine. The only known metabolite found in humans is trans-sulfoxide. The half-life of lamivudine is 10 to 15 hours and binds poorly to plasma proteins. Zidovudine is also well absorbed in the body and penetrates into the cerebrospinal fluid. Oral bioavailability is 75% and primarily metabolized by the liver by glucuronidation. The primary metabolite is GZDV, an inactive metabolite produced after first pass metabolism. The half-life of zidovudine is 0.5 to 3 hours and binds poorly to plasma proteins. Lamivudine and zidovudine are not extensively metabolized by CYP450 liver enzymes.
=== Distribution in plants === Didymin is found in a variety of citrus fruits, including mandarin oranges, sweet oranges, grapefruit, and lemons, as well as in Origanum vulgare (oregano). In immature dropped fruits of Citrus sinensis, didymin has been quantified alongside other flavanone glycosides such as hesperidin and narirutin, with its content being better preserved by freeze-drying than by hot-air oven drying. It was first identified in grapefruit as a tasteless rutinoside-type flavanone glycoside, in contrast to the bitter neohesperidoside-type glycosides such as naringin. It is also present in chenpi (dried citrus peel), a traditional ingredient in Chinese medicine.
== Dried plasma spot == This technology is similar to dried blood spot sampling however instead of collecting whole blood on a membrane, it separates red blood cells from plasma. A dried plasma spot (DPS) is usually a drop of capillary blood on a plasma separation card, the first membrane will filter all the red blood cells, while the second membrane aborbs the cell free plasma. This method is ideal for processing and storage of plasma.
Sources: en.wikipedia.org
In his public letter of resignation, he cited his reasons as being the lack of "the possibility of fulfilling, with the necessary total transparency, autonomy, and freedom, what Cuban Masonic legislation defines as required to carry out this responsibility." Alfonso Vidal said that the Grand Lodge was in the practice of "distorting Masonic Law." He also noted that because he had signed Decree 634, it was virtually impossible for him to have abandoned his post. He wrote that he was aware that he had been wrongfully terminated through an Extraordinary Session of the Supreme Court of Masonic Justice, and that those who signed his tacit resignation were being ordered to do so by the State Security Unit. He lamented the nature of the "...political gangsterism that works in the Grand Lodge of Cuba." Alfonso Vidal wrote that: "Cuban Masons have the right to know that our institution is under one of the greatest attacks it has received since January 1, 1959." He called back on the events surrounding the case of Grand Commander Viñas Alonso, and the letter that Viñas Alonso had sent to President Díaz-Canel. He said that the situation since Díaz-Canel had sent the State Security Unit after Viñas Alonso, the situation in Cuban Freemasonry had become increasingly difficult to operate within as an ethical and moral Grand Master. He could not fulfill his obligations as Grand Master for the fear of what actions the Cuban state might take against him. He also urged Cuban Freemasons to reject anyone from the Cuban intelligence community to ever again gain high office in the Grand Lodge.
=== Saudi Arabia === In Saudi Arabia, an MD must pass the Saudi Medical License Exam (SMLE) to apply for medical residency programs. The competitiveness of residency programs varies by specialty and region, with Plastic Surgery, Ophthalmology, Dermatology, and ENT being the most competitive. Residency durations range from 3 to 7 years, depending on the specialty. All residency programs include an end-of-training medical exam, which is conducted in English, as a requirement for board certification.
Respiratory stimulants: carotid chemoreceptor agonists (e.g. doxapram), 5-HT4 agonists (e.g. BIMU8), δ-opioid agonists (e.g. BW373U86) and AMPAkines (e.g. CX717) can all reduce respiratory depression caused by opioids without affecting analgesia, but most of these drugs are only moderately effective or have side effects which preclude use in humans. 5-HT1A agonists such as 8-OH-DPAT and repinotan also counteract opioid-induced respiratory depression, but at the same time reduce analgesia, which limits their usefulness for this application. Opioid antagonists (e.g. naloxone, nalmefene, diprenorphine) The initial 24 hours after opioid administration appear to be the most critical with regard to life-threatening OIRD, but may be preventable with a more cautious approach to opioid use. Patients with cardiac, respiratory disease and/or obstructive sleep apnoea are at increased risk for OIRD.
=== Litigation === This drug has been the subject of litigation; more than 13,000 people have sued Wyeth between 2002 and 2009. Wyeth and Pharmacia & Upjohn prevailed in the vast majority of hormone therapy cases previously set for trial through a combination of rulings by judges, verdicts by juries, and dismissals by plaintiffs themselves. Of the company's losses, two of the jury verdicts were reversed post-trial and others are being challenged on appeal. Wyeth also won five summary judgments on Prempro cases and had 15 cases voluntarily dismissed by plaintiffs. The company won dismissals in another 3,000 cases. In 2006, Mary Daniel, in a trial in Philadelphia, was awarded $1.5 million in compensatory damages as well as undisclosed punitive damages. As of 2010, Wyeth had won the last four of five cases, most recently in Virginia, finding that they were not responsible for the breast cancer of plaintiff Georgia Torkie-Tork. Wyeth has been quoted as saying "many risk factors associated with breast cancer have been identified, but science cannot establish what role any particular risk factor or combination play in any individual woman's breast cancer." Wyeth's counsel in the case also noted that in the WHI trial, 99.62% of women took the drug and "did not get breast cancer".
People today continue to honor Incan traditions and expand their knowledge in the building of rope bridges. "Each June in Huinchiri, Peru, four Quechua communities on two sides of a gorge join together to build a bridge out of grass, creating a form of ancient infrastructure that dates back at least five centuries to the Inca Empire." The previous Q’eswachaka Bridge is cut down and swept away by the Apurímac River current and a new bridge is built in its place. This tradition links the Quechua communities of the Huinchiri, Chaupibanda, Choccayhua, and Ccollana Quehue to their past ancestors.
Sources: en.wikipedia.org
== History == Sodium thiopental was discovered in the early 1930s by Ernest H. Volwiler and Donalee L. Tabern, working for Abbott Laboratories. It was first used in human beings on March 8, 1934, by Dr. Ralph M. Waters in an investigation of its properties, which were short-term anesthesia and surprisingly little analgesia. Three months later, Dr. John S. Lundy started a clinical trial of thiopental at the Mayo Clinic at the request of Abbott. Abbott continued to make the drug until 2004, when it spun off its hospital-products division as Hospira. Thiopental is famously associated with a number of anesthetic deaths in victims of the attack on Pearl Harbor. These deaths, relatively soon after the drug's introduction, were said to be due to excessive doses given to shocked trauma patients. However, evidence available through the freedom of information legislation suggested that the story was exaggerated. Of the 344 wounded that were admitted to the Tripler Army Hospital, only 13 did not survive, and it is unlikely that thiopentone overdose was responsible for more than a few of them.
== Measurement in biological fluids == Adrenaline may be quantified in blood, plasma, or serum as a diagnostic aid, to monitor therapeutic administration, or to identify the causative agent in a potential poisoning victim. Endogenous plasma adrenaline concentrations in resting adults usually are less than 10 ng/L, but they may increase by 10-fold during exercise and by 50-fold or more during times of stress. Pheochromocytoma patients often have plasma adrenaline levels of 1000–10,000 ng/L. Parenteral administration of adrenaline to acute-care cardiac patients can produce plasma concentrations of 10,000 to 100,000 ng/L.
==== 1960s–1970s ==== During the 1960s and 1970s, a number of new synthetic hallucinogens were introduced, with a notable example being the sale of highly potent tablets of DOM in San Francisco in 1967. There was little scope to prosecute people over drug analogues at this time, with new compounds instead being added to the controlled drug schedules one by one as they became a problem. One significant court case from this period was in 1973, when Tim Scully and Nicholas Sand were prosecuted for making the acetyl amide of LSD, known as ALD-52. At this time ALD-52 was not a controlled drug, but they were convicted on the grounds that in order to make ALD-52, they would have had to be in possession of LSD, which was illegal. The late 1960s also saw the introduction of various analogues of phencyclidine (PCP) to the illicit market, with Eticyclidine (PCE) first being detected in 1969.
Turner spoke with Jesse Mulligan after two health workers in the United Kingdom had suffered allergic reactions to the COVID-19 vaccine early in December 2020, and noted that some reaction to any vaccine is always a possibility but "good quality services delivering vaccines" were crucial to deal with these reactions. She suggested people with very severe allergies did need to be careful and it was important good information about the strengths and limitations of this vaccine, based on clinical data that was appropriately scrutinized, was shared by the media, scientists and the general community . In December 2021, Medsafe gave provisional approval for the vaccine to be used for children in age group of 5 - 11 year-olds in New Zealand. Turner told Corin Dann on Radio New Zealand that initial internal clinical data from the use of the vaccine for children overseas had shown it was being rolled out well. She noted that it didn't need to be mandatory but would protect children with other health issues or living in poverty, would limit the spread of COVID-19 in families and have less impact on schools. Prior to this approval, Turner acknowledged there were "pros and cons" about children getting the vaccine, but a strong case could be made that this would be in the interests of protecting the community. Turner stated that the gap for New Zealand children to get their second dose of COVID-19 vaccine needed to be longer than that for adults and maintaining it at eight weeks was likely to result in better immunity.
== Measurement == Formulas have been devised to estimate energy expenditure in humans, but they may not be accurate. Specifically they may not account for the effect of certain illnesses or the elderly. Not all formula are accurate in overweight or obese individuals. Traditional models for measuring human energy expenditure assumes that one's total daily energy expenditure (TDEE) is the simple additive sum of the measurement of each part of the body (e.g., resting metabolic rate, skeletal movement, and non-movement energy expenditures such as reproduction, digestion, immune system, etc.). Yet recent evidence suggests that the additive model may be accurate only up to an initial daily energy tipping point, after which the sum of the activities do not result in more energy expenditure, thus reflecting a constrained metabolic system. This is called the constrained daily energy expenditure model. Wearable devices can help estimate energy expenditure from physical activity but their accuracy varies.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.